Table 1.

Outcomes of LT in patients with unresectable iCCA.

Study	Design	Number of Patients	Neoadjuvant Therapy	Overall Survival
Sapisochin et al. (2016) [16]	Retrospective cohort multicenter. Incidental iCCA by pathological study.	48		1 year: 93% 3 years: 84% 5 years: 65%
McMillan et al. (2022) [18]	Prospective single-center case series.	18	Neoadjuvant chemotherapy (GemCis) and disease stability were required by radiological evaluation for at least six months. Treatments in addition to GemCis were heterogeneous: locoregional therapies, liver resection, and TT (IDH-1, FGFR, and PARP).	1 year: 100% 3 years: 71% 5 years: 57%
Ito et al. (2022) [19]	Retrospective, single-center, case series.	30	Neoadjuvant chemotherapy and or locoregional therapies.	1 year: 80% 3 years: 63% 5 years: 49%

Abbreviations: GemCis, Gemcitabine and Cisplatin; iCCA, intrahepatic cholangiocarcinoma; IDH, isocitrate dehydrogenase; FGFR, fibroblast growth factor receptor; and TT, targeted therapy.